Clinical trial · Observational
A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
A Pilot Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
NCT02370303CI-TRIAL-00032158completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to isolate and measure circulating tumor cells in the blood stream to advance detection of cancer and treatment monitoring. In this study, the investigators will utilize the novel technology for circulating tumor cell detection in order to evaluate their presence in patients with lung cancer.
Conditions
Conditions (11)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenocarcinoma | Adenocarcinoma | ONTOLOGY_EXACT | 0.90 |
| Cancer of Lung | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Cancer of the Lung | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Carcinoma, Non-small-cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
| Lung Neoplasms | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Neoplasms, Lung | Lung Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Neoplasms, Pulmonary | Neoplasm | ONTOLOGY_EXACT | 0.85 |
| Pulmonary Cancer | — | UNRESOLVED | — |
| Pulmonary Neoplasms | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Number and types of mutations in the primary tumor.
- timeFrame
- Within 1 year
- measure
- Number and type of mutations detectable in the matched circulating tumor cell samples.
- timeFrame
- Within 1 year
Secondary outcomes (1)
- measure
- Concordance of mutations detected by either method.
- timeFrame
- Within 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Stage IB and above non-small cell lung cancer or metastatic lung cancer * Age \>18 years old * Willing and able to consent to study * No prior history of neoadjuvant therapy. Exclusion Criteria: * Age \<18 years old * Unable to provide consent
References
Publications (0)
Data not yet available
No reference posted for this study.